看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
! U& Q/ K t. _8 \' h; Z2 p1 ?% ?- A6 r/ ]2 d
2 @7 A$ F; o5 U
Currently available feasibility data for possible combination strategies.
0 B9 a; U( e, R- _————————————————————————————————
& {* Y1 V1 n8 c% S5 }Combination Feasibility according to preliminary data
7 E X" I3 U1 G8 _——————————————————————————————————
7 o# O1 N% Z) gBevacizumab + sorafenib Yes, reduced dose
2 o9 @. U% N4 X6 T$ T# [; q. [2 X, z( @. @Bevacizumab + sunitinib† No 9 K( k0 o* L# J) K+ P
Bevacizumab + temsirolimus Yes 5 w" L& u- \5 p8 N8 G+ s, ^0 r
Bevacizumab + everolimus Yes + Q/ w/ g% ]* u. t: P d
Sorafenib + sunitinib ?
! [' k) ?) V+ v/ v' K1 OSorafenib + temsirolimus Yes, reduced dose
, w6 f; X8 I8 i+ I+ `5 ?6 pSorafenib + everolimus Yes, reduced dose 8 a5 _2 j2 ~) i* b
Sunitinib + temsirolimus† No
6 _! n& q4 P3 I$ |5 j- y; OSunitinib + everolimus ?
6 s2 c0 ?8 u! W: ?* Y( W3 \Temsirolimus + everolimus ?
2 z5 v( G0 i' I3 c$ ?————————————————————
" _- \- e/ o( I+ K& O" r6 Y" w) x†Led to US FDA warning.
6 m% A H3 e; ^1 y7 U( O?: As yet unattempted combination.. L$ ]; {) e' E/ w! u0 u: Y4 c
|